臨床検査68巻7号

2024年07月発行

今月の特集 骨髄腫と類縁疾患の検査学

画像検査

著者： 高須深雪¹ 飯田慎¹ 粟井和夫²

所属機関： ¹広島市立広島市民病院放射線診断科 ²広島大学大学院医系科学研究科放射線診断学研究室

ページ範囲：P.864 - P.871

Point

●単純X線検査は骨病変の評価に対し標準的な方法であったが，近年は新しい画像診断法に置き換えられつつある．単純X線検査は偽陰性率が高く，再現性が低い傾向がある．

●CTは小さな局所性骨病変の検出感度が高く，任意断面への再構成が可能である．びまん性骨減少症を示す場合は骨粗鬆症と鑑別できない．病変の疾患活動性は評価できない．

●MRIは組織間コントラストが高く，軟部腫瘤の検出や骨髄腔への腫瘍細胞浸潤の評価に有用である．治療後に活動性を失った病変が消失せず，画像上持続することが多い．

参考文献

1）Rajkumar SV, Dimopoulos MA, Palumbo A, et al：International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol　15：e538-e548，2014

2）日本血液学会（編）：造血器腫瘍診療ガイドライン2023年版　第3版，金原出版，p382，2023

3）Lacy MQ, Gertz MA, Hanson CA, et al：Multiple myeloma associated with diffuse osteosclerotic bone lesions: a clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). Am J Hematol　56：288-293，1997

4）Lütje S, de Rooy JW, Croockewit S, et al：Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol　88：1161-1168，2009

5）Edelstyn GA, Gillespie PJ, Grebbell FS：The radiological demonstration of osseous metastases. Experimental observations. Clin Radiol　18：158-162，1967

6）Mettler FA Jr, Huda W, Yoshizumi TT, et al：Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology　248：254-263，2008

7）Svahn TM, Peric L, Ast JC：Influence of Different Arm Positions in the Localizer Radiograph(s) on Patient Dose during Exposure-Controlled CT Examinations of the Neck to Pelvis. Tomography　7：313-322，2021

8）GOV.UK：Public Health England. Patient dose information: guidance, 2008（www.gov.uk/government/publications/medical-radiation-patient-doses/patient-dose-information-guidance）（最終アクセス：2024年4月10日）

9）Radiological Society of North America (RSNA)：Radiation Dose. Radiation Dose from X-Ray and CT Exams（https://www.radiologyinfo.org/en/info/safety-xray）（最終アクセス：2024年4月10日）

10）Hillengass J, Moulopoulos LA, Delorme S, et al：Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J　7：e599，2017

11）Wang J, Shen N, Shen X, et al：Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease. Ann Med　55：2281657，2023

12）Healy CF, Murray JG, Eustace SJ, et al：Multiple myeloma: a review of imaging features and radiological techniques. Bone Marrow Res　2011：583439，2011

13）Surgeon's Committee of the Chinese Myeloma Working Group of the International Myeloma Foundation：Consensus on Surgical Management of Myeloma Bone Disease. Orthop Surg　8：263-269，2016

14）Zamagni E, Nanni C, Patriarca F, et al：A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica　92：50-55，2007

15）Padhani AR, van Ree K, Collins DJ, et al：Assessing the relation between bone marrow signal intensity and apparent diffusion coefficient in diffusion-weighted MRI. AJR Am J Roentgenol　200：163-170，2013

16）Zajick DC Jr, Morrison WB, Schweitzer ME, et al：Benign and malignant processes: normal values and differentiation with chemical shift MR imaging in vertebral marrow. Radiology　237：590-596，2005

17）Omoumi P：The Dixon method in musculoskeletal MRI: from fat-sensitive to fat-specific imaging. Skeletal Radiol　51：1365-1369，2022

18）Takasu M, Tanitame K, Baba Y, et al：Does chemical shift imaging offer a biomarker for the diagnosis and assessment of disease severity in multiple myeloma?: A cross-sectional study. Medicine (Baltimore)　100：e24358，2021

19）Takahara T, Imai Y, Yamashita T, et al：Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med　22：275-282，2004

20）Yoshida S, Takahara T, Arita Y, et al：Whole-body diffusion-weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond. Int J Urol　28：502-513，2021

21）Mai EK, Hielscher T, Kloth JK, et al：A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. Haematologica　100：818-825，2015

22）Caers J, Withofs N, Hillengass J, et al：The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica　99：629-637，2014

23）Park HY, Kim KW, Yoon MA, et al：Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response. Cancer Imaging　20：14，2020

24）Rasche L, Alapat D, Kumar M, et al：Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia　33：1713-1722，2019

25）Hillengass J, Usmani S, Rajkumar SV, et al：International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol　20：e302-e312，2019

26）Regelink JC, Minnema MC, Terpos E, et al：Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol　162：50-61，2013

27）Bredella MA, Steinbach L, Caputo G, et al：Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol　184：1199-1204，2005

F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol　35：2911-2918，2017

29）Rajkumar SV, Harousseau JL, Durie B, et al：Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood　117：4691-4695，2011

30）Kumar S, Paiva B, Anderson KC, et al：International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol　17：e328-e346，2016

31）Greven KM, Williams DW 3rd, McGuirt WF Sr, et al：Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck　23：942-946，2001

32）Quach B, Lind K, Koo P, et al：Confounding bone marrow findings in lymphoma patients due to granulocyte colony stimulating factor on FDG PET/CT. J Nucl Med　59（Suppl 1）：587，2018

33）Parmar H, Rath T, Castillo M, et al：Imaging of focal amyloid depositions in the head, neck, and spine: amyloidoma. AJNR Am J Neuroradiol　31：1165-1170，2010

34）Moy LN, Mirza M, Moskal B, et al：Pulmonary AL amyloidosis: A review and update on treatment options. Ann Med Surg (Lond)　80：104060，2022

35）Said SM, Sethi S, Valeri AM, et al：Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol　8：1515-1523，2013

36）Ohyama T, Shimokama T, Yoshikawa Y, et al：Splenic amyloidosis: correlations between chemical types of amyloid protein and morphological features. Mod Pathol　3：419-422，1990

37）Pandarinath GS, Levine SM, Sorokin JJ, et al：Selective massive amyloidosis of the small intestine mimicking multiple tumors. Radiology　129：609-610，1978

38）Eghtedari M, Dogan BE, Gilcrease M, et al：Imaging and pathologic characteristics of breast amyloidosis. Breast J　21：197-199，2015

39）Shi X, Hu S, Yu X, et al：Clinicopathologic analysis of POEMS syndrome and related diseases. Clin Lymphoma Myeloma Leuk　15：e15-e21，2015